Studies in follow-up

Bayer 20604/Oceanic Stroke:
A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA
Sponsor: Bayer AG
Phase: 3
Active Subjects: 3
Principal Investigator: Dr. Irfan Altafullah